Combined sales of diabetes drugs glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter-2 (SGLT-2) inhibitors exceeded $8bn in 2017, according to a study by GlobalData.
The study covered seven major pharmaceutical markets, the US, France, Italy, Germany, Spain, the UK, and Japan, also known as the 7MM.
These type 2 diabetes (T2D) drug classes continue to obtain substantial market share through their glycemic and non-glycemic benefits such as blood pressure reductions and cardiovascular (CV) benefits, according to company.
GlobalData managing healthcare analyst Jesus Cuaron said: “Across the 7MM, there are currently 14 approved GLP-1 receptor agonists and SGLT-2 inhibitors collectively (not including combination varieties).
“The timeline of approved GLP-1 receptor agonists and SGLT-2 inhibitors in the 7MM, confirms that Novo Nordisk’s Ozempic (semaglutide) and Merck and Pfizer’s Steglatro (ertugliflozin) received the most recent regulatory approvals in 2017.”
Ozempic is an injectable GLP-1 receptor agonist that demonstrated significant decrease in glycated haemoglobin (A1c) and major adverse CV events risk during clinical trials.
Steglatro is a SGLT-2 inhibitor that has been observed to deliver significant reductions in A1c levels. The drug is also said to have multiple non-glycemic advantages such as weight loss and systolic blood pressure reduction.
Scheduled for release in the US over the coming months, both Ozempic and Steglatro are predicted to gain a significant T2D market share.
Despite the array of drugs currently available for T2D, additional treatments are required for patients to manage the chronic disease. Key opinion leaders interviewed by GlobalData said that GLP-1 receptor agonists and SGLT-2 inhibitors could be promising additions to current treatments.
Cuaron added: “As such, we believe the GLP-1 receptor agonists and SGLT-2 inhibitors will experience the fastest growth of any T2D drug class.”